Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment
Authors:
Open Access
- 24 June 2012
- journal article
- research article
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 109 (3) , 382-390
Abstract
Renal excretion is the primary route for the elimination of sugammadex. We evaluated the dialysability of sugammadex and the sugammadex–rocuronium complex in patients with severe renal impairment in the intensive care unit (ICU). Six patients in the ICU with acute severe renal impairment received general anaesthesia for transoesophageal echocardiography, to replace their tracheal tubes, or for bronchoscopy. Five of the six patients were in the ICU after cardiac/vascular surgery and one for pneumonia-induced respiratory failure. They all received rocuronium 0.6 mg kg−1, followed 15 min later by sugammadex 4.0 mg kg−1. Two patients were studied for two dialysis episodes and four patients for four episodes. Rocuronium and sugammadex concentrations were measured in plasma and dialysate at several time points before, during, and after high-flux dialysis. Dialysis clearance in plasma and dialysate, and reduction ratio (RR) (the extent of the plasma concentration reduction at the end of a dialysis episode when compared with before dialysis) were calculated for each dialysis episode. Dialysis episodes lasted on average 6 h. Observed RRs indicated mean reductions of 69% and 75% in the plasma concentrations of sugammadex and rocuronium, respectively, during the first dialysis episode. Reductions were around 50% during sequential dialysis episodes. On average, dialysis clearance of sugammadex and rocuronium in blood was 78 and 89 ml min−1, respectively. Haemodialysis using a high-flux dialysis method is effective in removing sugammadex and the sugammadex–rocuronium complex in patients with severe renal impairment.Keywords
Funding Information
- Merck Sharp & Dohme Corp.
This publication has 27 references indexed in Scilit:
- Sugammadex is cleared rapidly and primarily unchanged via renal excretionBiopharmaceutics & Drug Disposition, 2011
- Safety, Tolerability and Pharmacokinetics of Sugammadex Using Single High Doses (Up to 96 mg/kg) in Healthy Adult SubjectsClinical Drug Investigation, 2010
- Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trialEuropean Journal of Anaesthesiology, 2010
- Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmineBMC Anesthesiology, 2010
- Sugammadex Provides Faster Reversal of Vecuronium-Induced Neuromuscular Blockade Compared with Neostigmine: A Multicenter, Randomized, Controlled TrialAnesthesia & Analgesia, 2010
- Preclinical pharmacology of sugammadexJournal of Critical Care, 2009
- Reversal of Profound Rocuronium-induced Blockade with SugammadexAnesthesiology, 2008
- Sugammadex Reversal of Rocuronium-Induced Neuromuscular Blockade: A Comparison with Neostigmine???Glycopyrrolate and Edrophonium???AtropineAnesthesia & Analgesia, 2007
- Effective Reversal of Moderate Rocuronium- or Vecuronium-induced Neuromuscular Block with Sugammadex, a Selective Relaxant Binding AgentAnesthesiology, 2007
- Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular blockBritish Journal of Anaesthesia, 2005